Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc.
Your view on PRAX
Overview
What the company does, where it operates, and who runs it.
About Praxis Precision Medicines, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Marcio Silva De'Souza
- Headquarters
- 99 High Street, Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Marcio Silva De'Souza
- Headquarters
- 99 High Street, Boston, MA, US
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance.
Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.
The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy.
It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs.
The company was incorporated in 2015 and is based in Boston, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Praxis Precision Medicines, Inc., and the rating behind it. PRAX last traded at $334.58; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Praxis Precision Medicines, Inc.. Starting points for Praxis Precision Medicines, Inc.: EPS -$11.64, beta 2.78 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Praxis Precision Medicines, Inc.. Praxis Precision Medicines, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Praxis Precision Medicines, Inc.. Trailing twelve-month EPS for Praxis Precision Medicines, Inc. stands at -$11.64. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Praxis Precision Medicines, Inc.. Praxis Precision Medicines, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Praxis Precision Medicines, Inc. valued side by side against its closest peers. Praxis Precision Medicines, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Praxis Precision Medicines, Inc., and how their positions are changing. At a $9.33B market value, institutional positions materially move Praxis Precision Medicines, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Praxis Precision Medicines, Inc. executives and directors. Shares of Praxis Precision Medicines, Inc. have traded between $26.70 and $206.71 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Praxis Precision Medicines, Inc.. Praxis Precision Medicines, Inc. is a $9.33B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Praxis Precision Medicines, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Praxis Precision Medicines, Inc.. Coverage tracks Praxis Precision Medicines, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.